ストックスクリーナーアプリを入手
2.43
58.82%
0.90
プレマーケット:
2.66
0.23
+9.47%
前日終値:
$1.53
開ける：
$1.51
24時間の取引高:
24.69M
Relative Volume:
10.36
時価総額：
$79.44M
収益：
-
当期純損益:
$-87.23M
株価収益率:
-0.8182
EPS:
-2.97
ネットキャッシュフロー:
$-82.77M
1週間 パフォーマンス:
+68.75%
1か月 パフォーマンス:
+30.65%
6か月 パフォーマンス:
-74.61%
1年 パフォーマンス:
-84.18%
1日の値動き範囲:
$1.50
$2.53
1週間の範囲:
$1.345
$4.48
52週間の値動き範囲:
$1.16
$19.30
Pepgen Inc Stock (PEPG) Company Profile
PEPG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
2.43 | 79.44M | 0 | -87.23M | -82.77M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.50 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.78 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.70 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.10 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
278.38 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-07-31 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-21 | 開始されました | H.C. Wainwright | Buy |
Pepgen Inc (PEPG) 最新ニュース
What is HC Wainwright’s Estimate for PepGen FY2025 Earnings? - Defense World
Wedbush Weighs in on PepGen’s Q1 Earnings (NASDAQ:PEPG) - Defense World
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz? - Asianet Newsable
Stock market news: Binah Capital Group +184.15%, PepGen +35.25% among top gainers during midday trading - Business Upturn
Promising Prospects for PepGen Inc.: Buy Rating Affirmed Amid Positive DM1 Treatment Developments - TipRanks
What is HC Wainwright’s Estimate for PepGen Q1 Earnings? - Defense World
PepGen CFO Noel Donnelly sells $2,565 in stock By Investing.com - Investing.com South Africa
PepGen general counsel DeLena sells $2,405 in stock - Investing.com India
PepGen general counsel DeLena sells $2,405 in stock By Investing.com - Investing.com South Africa
PepGen CFO Noel Donnelly sells $2,565 in stock - Investing.com India
Biotech Alert: Searches spiking for these stocks today - TipRanks
PepGen reports positive initial data from Phase I DM1 therapy trial - MSN
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
PepGen Inc. Reports Positive Trial Results and Financials - TipRanks
PepGen (NASDAQ:PEPG) Receives “Buy” Rating from HC Wainwright - Defense World
Sell Rating on PepGen Inc. Amid Clinical and Regulatory Challenges - TipRanks
What's Driving the Market Sentiment Around PepGen? - Benzinga
PepGen stock price target cut to $14 by Stifel analysts - Investing.com Australia
Pepgen rallies as early data suggest sporting chance in DM1 - BioWorld Online
PepGen Drug Shows Signs of Topping Rivals in Rare Muscle Disease With No Approved Meds - MedCity News
Biotech Stock PepGen Inc. (NASDAQ: PEPG) Makes NASDAQ Top Gainers List on Financial Results and Update - Investorideas.com newswire
Stock market news: AtlasClear Holdings +282.98%, PepGen +109.42% among top gainers during midday trading - Business Upturn
PepGen Inc. Announces Positive FREEDOM-DM1 Trial Results - MSN
Promising Initial Data and Safety Profile Boost PepGen’s FREEDOM-DM1 Trial Outlook - TipRanks
PepGen data ‘very encouraging’ for program, says H.C. Wainwright - TipRanks
Why PepGen (PEPG) Stock Is Skyrocketing Today - Benzinga
Stock market today: AtlasClear Holdings +318.09%, PepGen +151.82% among top gainers in early trading - Business Upturn
PepGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 -February 24, 2025 at 07:01 am EST - Marketscreener.com
PepGen initial DM1 data ‘a clear win,’ says Stifel - TipRanks
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1 - BioSpace
PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights - Business Wire
PepGen reports promising DM1 drug trial results - Investing.com
PepGen announces initial clinical data from cohorts in FREEDOM-DM1 trial - TipRanks
PepGen Inc. SEC 10-K Report - TradingView
Can PepGen's 29% Splicing Success Transform DM1 Treatment? Key Trial Data Revealed - StockTitan
PepGen stock plunges to 52-week low at $1.16 amid market challenges - MSN
Taking on analysts’ expectations and winning: PepGen Inc (PEPG) - SETE News
PEPG’s 2023 Market Dance: Down -64.64% – Time to Invest? - The InvestChronicle
why PepGen Inc [PEPG] is a Good Choice for Investors After New Price Target of $12.80 - The DBT News
FY2029 Earnings Estimate for PepGen Issued By HC Wainwright - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - PR Newswire
Market Update: PepGen Inc (PEPG) Sees Negative Movement, Closing at 1.25 - The Dwinnex
HC Wainwright Cuts PepGen (NASDAQ:PEPG) Price Target to $16.00 - MarketBeat
H.C. Wainwright cuts PepGen stock target to $16, maintains Buy rating - Investing.com India
JPMorgan Chase & Co. Increases Holdings in PepGen Inc. (NASDAQ:PEPG) - Defense World
HC Wainwright Lowers PepGen (NASDAQ:PEPG) Price Target to $16.00 - Defense World
PepGen price target lowered to $16 from $26 at H.C. Wainwright - Yahoo Finance
PepGen stock plunges to 52-week low of $1.76 amid market challenges - Investing.com
Pepgen Inc (PEPG) 財務データ
収益
当期純利益
現金流量
EPS
1.22%
0.03%
大文字化:
|
ボリューム (24 時間):